These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Effect of conversion from ESA with shorter half-life to CERA once monthly for maintaining Hb concentration in pre-dialysis CKD patients. Choi JY; Yang CW; Kim YH; Joo KW; Yoo TH; Lee KW; Lee SH; Moon JY; Shin SK; Huh W; Kim NH; Park SH; Kim CD; Kim YL Kidney Blood Press Res; 2013; 37(4-5):259-68. PubMed ID: 24022228 [TBL] [Abstract][Full Text] [Related]
5. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent]. Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529 [TBL] [Abstract][Full Text] [Related]
6. Monthly Continuous Erythropoietin Receptor Activator Versus Weekly Epoetin-Beta, Similar Hemoglobinization but Different Anisocytosis Degree in Hemodialysis Patients: A Randomized Controlled Trial. Uriol-Rivera MG; Obrador-Mulet A; Jimenez-Mendoza S; Corral-Baez A; Perianez-Parraga L; Garcia-Alvarez A; de la Prada FJ J Hematol; 2021 Dec; 10(6):255-265. PubMed ID: 35059087 [TBL] [Abstract][Full Text] [Related]
7. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U; Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of a simple dosage scheme to convert from shorter-acting erythropoiesis-stimulating agent to continuous erythropoietin receptor activator in kidney transplantation patients. Sánchez-Escuredo A; Batista F; Cases A; Torregrosa JV Transplant Proc; 2015; 47(1):73-5. PubMed ID: 25645774 [TBL] [Abstract][Full Text] [Related]
9. Long-term maintenance of hemoglobin levels in hemodialysis patients treated with bi-weekly epoetin beta pegol switched from darbepoetin alfa: a single-center, 12-month observational study in Japan. Kawai T; Kusano Y; Yamada K; Ueda C; Kawai A; Masaki T J Artif Organs; 2019 Jun; 22(2):146-153. PubMed ID: 30426250 [TBL] [Abstract][Full Text] [Related]
10. Twice-monthly administration of a lower dose of epoetin beta pegol can maintain adequate hemoglobin levels in hemodialysis patients. Morikami Y; Fujimori A; Okada S; Kumei M; Mizobuchi N; Sakai M Ther Apher Dial; 2015 Apr; 19(2):138-43. PubMed ID: 25402974 [TBL] [Abstract][Full Text] [Related]
12. Dose equivalence between continuous erythropoietin receptor activator (CERA), Darbepoetin and Epoetin in patients with advanced chronic kidney disease. Vega A; Abad S; Verdalles U; Aragoncillo I; Velazquez K; Quiroga B; Escudero V; López-Gómez JM Hippokratia; 2014; 18(4):315-8. PubMed ID: 26052197 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of recombinant human erythropoietin beta in maintaining common haemoglobin targets in routine clinical practice in Europe: the GAIN study. Rath T; Mactier RA; Weinreich T; Scherhag AW; Curr Med Res Opin; 2009 Apr; 25(4):961-70. PubMed ID: 19254204 [TBL] [Abstract][Full Text] [Related]
14. Monthly CERA treatment maintains stable hemoglobin levels in routine clinical practice of peritoneal dialysis patients. González MT; Ramos R; Vera M; Barbosa F; Garcia C; Garcia I; González-Segura C; Cuxart M; Teixidó J; José de la Cruz J Ren Fail; 2013; 35(3):314-9. PubMed ID: 23356501 [TBL] [Abstract][Full Text] [Related]
15. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis. Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of once-monthly continuous erythropoietin receptor activator in patients with chronic renal anemia. Locatelli F; Mandolfo S; Menegato Adorati M; Villa G; Tarchini R; Pizzarelli F; Conte F; Guastoni C; Ricciardi B; Crotta A J Nephrol; 2013; 26(6):1114-21. PubMed ID: 24052462 [TBL] [Abstract][Full Text] [Related]
17. A single arm, prospective, open label, multicentre study for evaluation of efficacy and safety of IV CERA for treatment of chronic renal anaemia in dialysis patients not currently treated with ESA. Nainan GK; Pathak VR; Dalal SS; Saxena S; Mittal D; Raju TR; Gokulnath ; Isaac R; Rajapurkar MM; Rana DS; Shah BV; Ray DS; Thiagarajan CM; Jha RM; Kukreja AA; Pophale RR J Assoc Physicians India; 2014 Mar; 62(3):232-6. PubMed ID: 25327065 [TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin beta in peritoneal dialysis patients with chronic renal anaemia. Grzeszczak W; Sulowicz W; Rutkowski B; de Vecchi AF; Scanziani R; Durand PY; Bajo A; Vargemezis V; Nephrol Dial Transplant; 2005 May; 20(5):936-44. PubMed ID: 15769814 [TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety of CERA in anemia correction in predialysis patients--Croatian experience]. Bubić I; Prkacin I; Racki S Acta Med Croatica; 2012 Oct; 66 Suppl 2():42-6. PubMed ID: 23513415 [TBL] [Abstract][Full Text] [Related]
20. Cost should be the principal determinant of choice of erythropoiesis-stimulating agent in chronic haemodialysis patients. Courtney AE; McNamee PT; Maxwell AP Nephron Clin Pract; 2007; 107(1):c14-9. PubMed ID: 17664890 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]